• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
Menu
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

United Therapeutics gets orphan drug designation for treprostinil for the treatment of IPF

According to United Therapeutics, the FDA has granted orphan drug designation to treprostinil for the treatment of patients with idiopathic pulmonary fibrosis (IPF), with the designation’s benefits applying to both Tyvaso inhalation solution and Treprostinil Technosphere dry powder treprostinil. United Therapeutics also said that the FDA has cleared the company’s IND for the Phase 3 TETON study of Tyvaso in IPF patients, and enrollment is expected to begin in 2021.

In February 2020, United Therapeutics announced that the Phase 3 INCREASE study of Tyvaso for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) met its primary endpoint. The company has been partnered with MannKind on the development of the treprostinil DPI since 2018. Earlier this year, United Therapeutics filed a patent infringement suit against Liquidia Technologies, which is developing a dry powder treprostinil for the treatment of pulmonary arterial hypertension (PAH); Liquidia recently received a CRL from the FDA in response to its NDA for that DPI.

United Therapeutics Chairman and CEO Martine Rothblatt commented, “We’re excited that treprostinil has received orphan drug designation, as it validates our drive to address orphan diseases, like IPF, with a significant unmet need. TETON represents a significant move outside the pulmonary hypertension space, but based on data collected during the recent INCREASE study we’re confident that inhaled treprostinil can help address clinical gaps presented by existing therapies in IPF.”

Read the United Therapeutics press release.

Share

published on December 9, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • May 13-May 14: Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course 24, online
  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews